KYLE BARTSCHMID: Open Payments
NPI 1528460276 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$798 in 35 payments from 9 companies in 2025. Trend: 2023 $405 · 2024 $307 · 2025 $798
Food & beverage: $658Education: $140
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 13 | $293 |
| GENZYME CORPORATION | 8 | $184 |
| Optinose US, Inc. | 3 | $69 |
| AstraZeneca Pharmaceuticals LP | 3 | $65 |
| Novartis Pharmaceuticals Corporation | 2 | $48 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $47 |
| Amgen Inc. | 1 | $34 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Organon LLC | 1 | $23 |
Products named: DUPIXENT, Xhance, NEFFY, TEZSPIRE, Rhapsido, TRELEGY ELLIPTA, AIRSUPRA, NUCALA.
Industry payments across TX — which companies pay providers there.
